Clinical Trial Update: Korean Post-marketing Surveillance for Sprycel®

View source ↗

Summary

This is a completed Korean post-marketing surveillance study of Sprycel (dasatinib). It covered patients with chronic myelomonocytic leukemia and leukemia/lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Myelomonocytic Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Leukemia, Myelomonocytic, Chronic, Leukemia-Lymphoma | Status: COMPLETED